Sponsor - Apellis (Closed to Enrollment)
Study: GALE APL2-305
A PHASE 3, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PEGCETACOPLAN IN SUBJECTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
https://clinicaltrials.gov/ct2/show/NCT04770545?term=Apellis+GALE&draw=2&rank=1
Sponsor - ANNEXON (Closed to Enrollment)
Study: ARCHER ANX007-GA-01
A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
https://clinicaltrials.gov/ct2/show/NCT04656561?term=ARCHER&draw=2&rank=2
Previous Dry AMD Studies:
2020 - 2022
Sponsor - Apellis
Study: OAKS APL2-304
A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
2020 - 2021
Sponsor - Iveric Bio
Study: GATHER2 ISEE2008
A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL ADMINISTRATION OF ZIMURA (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION
2020 - 2021
Sponsor - Gemini Therapeutics
Study: ReGAtta GEM-CL-10302
A Multicenter, Open-label, Multiple Dose Study in Patients with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103
2021 - 2022
Sponsor – Genentech
Study: GALLEGOLE GR42558
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF INTRAVITREAL INJECTIONS OF FHTR2163 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE RELATED MACULAR DEGENERATION (GAllegOLE)
2019 -2021
Sponsor – Genentech
Study: GALLEGO GR40973
A PHASE II, MULTICENTER, RANDOMIZED, SINGLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND EFFICACY OF INTRAVITREAL INJECTIONS OF FHTR2163 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION (GALLEGO)
https://clinicaltrials.gov/ct2/show/NCT03972709?term=gallego&rank=1
2019 - 2019
Sponsor - Ionis
Study: GOLDEN ISIS696844-CS5
A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-Lrx, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)
https://clinicaltrials.gov/ct2/show/NCT03815825?term=isis+696844&rank=1
2019 - 2020
Sponsor - Stealth BioTherapeutics
Study: SPIAM-202
APhase 2, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic Atrophy
https://clinicaltrials.gov/ct2/show/NCT03891875?term=spiam&rank=1
Principal Investigator, 2016 - 2017
Sponsor: Genentech/Roche
Study: OMASPECT
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A ROCHE-SPONSORED STUDY
https://clinicaltrials.gov/ct2/show/NCT02745119?term=OMASPECT&rank=1
Principal Investigator, 2014 - 2017
Sponsor: Genentech/Roche
Study: CHROMA – Geographic Atrophy (GA)
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
https://clinicaltrials.gov/ct2/results?term=CHROMA&Search=Search